Skip to main content

Month: March 2021

AB Science communique ce jour une mise à jour du calendrier des résultats finaux de son étude de phase 3 du masitinib (AB12003) dans le traitement du cancer de la prostate métastatique

                                                                                                                                                                                                                   COMMUNIQUE DE PRESSE MISE A JOUR CONCERNANT L’ETUDE DE PHASE 3 DU MASITINIB (AB12003) DANS LE CANCER DE LA PROSTATE METASTATIQUE HORMONO-RESISTANT (mCRPC) ELIGIBLE A LA CHIMIOTHERAPIE Paris, 31 mars 2021, 18h AB Science SA (NYSE Euronext – FR0010557264 – AB) communique ce jour une mise à jour du calendrier des résultats finaux de son étude de phase 3 du masitinib (AB12003) dans le traitement du cancer de la prostate métastatique hormono-résistant (mCRPC) éligible à la chimiothérapie. Les résultats finaux de l’étude seront disponibles en avril 2021. A propos de l’étude AB12003 L’étude AB12003 est une étude internationale,...

Continue reading

Síminn hf. – Breytingar á hlutafé

Í samræmi við 84. gr. laga um verðbréfaviðskipti nr. 108/2007, um breytingu á hlutafé eða atkvæðisrétti útgefanda, tilkynnist hér með að heildarfjöldi hluta í Símanum hf. er í dag, 31. mars 2021, kr. 7.540.000.000 að nafnverði og fylgir eitt atkvæði hverjum hlut í félaginu. Félagið á 30.859.967 eigin hluti. Vísað er til tilkynningar frá félaginu um lækkun hlutafjár frá 18. mars 2021. Nánari upplýsingar veitir Davíð Scheving fjárfestatengill Símans í netfangi fjarfestatengsl@siminn.is.

Continue reading

Ethan Allen Opens New Design Centers and Strengthens North American Manufacturing

DANBURY, CT, March 31, 2021 (GLOBE NEWSWIRE) — Ethan Allen has continued to strengthen its retail position by relocating and redesigning multiple Design Centers during the past 12 months. The company also continues to strengthen its manufacturing in North America, where about 75% of its products are made. These moves capitalize on the brand’s ongoing commitment to combining technology with personal service and growing its strong North American manufacturing base. New and relocated Design Centers opened in past 12 months include San Mateo, California; Green Bay, Wisconsin; Oxnard, California; Towson, Maryland; Alpharetta, Georgia; and last week, in Portland, Oregon. “Ethan Allen has evolved into an all-in-one, whole-home custom design house,” stated Farooq Kathwari, Chairman and CEO of Ethan Allen Interiors Inc. “Our newest Design...

Continue reading

Healthcare Analytics Market Size 2021 | Is projected reach USD 80.21 billion by 2026

Pune, India, March 31, 2021 (GLOBE NEWSWIRE) — According to the report, Healthcare Analytics market size is projected reach USD 80.21 billion by 2026. Healthcare analytics market was valued at USD 11.59 billion in 2018. The advancement in technologies along with growing venture capital funding will aid the market in the region. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/healthcare-analytics-market-102641 Cerner Corporation, an American health information technology solutions and services company launched a trailblazing platform, project Apollo. The new cognitive platform will provide computing resources to its healthcare users. The cloud-based automation platform is built on AWS infrastructure for speedy innovations to eliminate manual steps that cast obstructions...

Continue reading

[Correction] AYRO Announces Year-End 2020 Financial Results and Provides Corporate Update

Earnings conference call to be held Wednesday, March 31, 2021 at 8:30 a.m. ET AUSTIN, TX, March 31, 2021 (GLOBE NEWSWIRE) — AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of light-duty, short-haul, and last-mile delivery electric vehicles (EVs), today announced financial results for its fiscal year ended 12/31/20. Fiscal Year 2020 Financial Highlights:Revenue of $1.6 million (+80% YOY) in FY2020 vs. $0.9 million for FY2019 Net Loss Attributable to Common Stockholders of ($11.2) million in FY2020 vs. ($8.6) million in FY2019 Adjusted EBITDA loss of ($7.8) million for FY 2020 vs. ($4.4) million for FY2019 Total Cash of $36.5 million as of December 31, 2020 vs. $0.6 million as of December 31, 2019 Total debt of $0.02 million as of December 31, 2020 vs. $1.3 million as of December 31, 2019Recent...

Continue reading

Admiral Markets AS audited annual report 2020

Admiral Markets AS püstitas 2020. aastal tegutsemisaja kasumirekordi 2020. aasta oli Admiral Markets AS tegutsemisaja edukaim. Ettevõtte puhaskasum oli 20,3 miljonit eurot, mida on 340% rohkem kui aasta varem. Tehingute maht kasvas aastaga 110%. Admiral Markets AS-i kauplemise netotulu kasvas möödunud aastal 47,1 miljoni euroni. 2019. aastal oli vastav näitaja 23,2 miljonit eurot. Puhaskasumi marginaal oli 2020. aasta kokkuvõttes 43% (2019: 20%). 2020. aastal tegid Admiral Markets AS kliendid 66,9 miljonit tehingut, võrdluses aasta varasemaga, mil vastav näitaja oli 31,8 miljonit.  Admiral Markets AS juhatuse esimees Sergei Bogatenkov ütles, et möödunud aasta rekordtulemused viisid ettevõtte märgatavalt lähemale 2030. aastaks seatud eesmärgile- pakkuda finantsvabadust 10 miljonile kliendile. “Loomulikult oleme äriliste tulemuste üle väga...

Continue reading

Admiral Markets AS auditeeritud aastaaruanne 2020

Admiral Markets AS püstitas 2020. aastal tegutsemisaja kasumirekordi 2020. aasta oli Admiral Markets AS tegutsemisaja edukaim. Ettevõtte puhaskasum oli 20,3 miljonit eurot, mida on 340% rohkem kui aasta varem. Tehingute maht kasvas aastaga 110%. Admiral Markets AS-i kauplemise netotulu kasvas möödunud aastal 47,1 miljoni euroni. 2019. aastal oli vastav näitaja 23,2 miljonit eurot. Puhaskasumi marginaal oli 2020. aasta kokkuvõttes 43% (2019: 20%). 2020. aastal tegid Admiral Markets AS kliendid 66,9 miljonit tehingut, võrdluses aasta varasemaga, mil vastav näitaja oli 31,8 miljonit.  Admiral Markets AS juhatuse esimees Sergei Bogatenkov ütles, et möödunud aasta rekordtulemused viisid ettevõtte märgatavalt lähemale 2030. aastaks seatud eesmärgile- pakkuda finantsvabadust 10 miljonile kliendile. “Loomulikult oleme äriliste tulemuste üle väga...

Continue reading

African Gold Group Stock Option Grant Clarification

TORONTO, March 31, 2021 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) clarifies that further to a press release issued earlier today that announced a grant of a total of 2,800,000 stock options to certain officers, directors and consultants of the Company pursuant to the Company’s stock option plan at an exercise price of $0.115 per option, the exercise price should have read $0.15 per option. All other terms of the options that are in force for a period of five years from the date of grant remain the same. This grant of options is subject to the approval of the TSX Venture Exchange. About African Gold Group African Gold Group is a TSX Venture Exchange (TSX-V: AGG) listed exploration and development company with a focus on building Africa’s next mid-tier gold producer. The Company has a highly...

Continue reading

Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021

MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced that it will hold a shareholder conference call on Thursday May 6, 2021 at 9:00 AM ET. On this upcoming conference call, Generex President and Chief Executive Officer Joseph Moscato will provide a comprehensive update to shareholders detailing the company’s most recent corporate developments and achievements since their last call. Mr. Moscato will discuss advancements regarding its FDA IND submission where Generex has surpassed the final threshold and has completed its GMP manufacturing of its vaccine...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.